Boosting levels of the chemical messenger serotonin makes mice that model autism more social, according to a study published [August 8] in Nature. The study suggests the approach may do the same in people with autism. It also offers an explanation for why antidepressants do not ease autism traits: They may increase serotonin levels too slowly to be effective.
The researchers used a technique that rapidly increases serotonin levels in the nucleus accumbens, a brain region that mediates social reward. “Somehow, the release of serotonin in the nucleus accumbens really plays an important role in enhancing sociability,” says lead researcher Robert Malenka.
Decades of research have suggested a connection between serotonin and autism. About 10 years ago, this led researchers to test antidepressants, which increase serotonin levels by blocking its reabsorption into neurons, as a treatment for autism. However, in several trials, antidepressants such as fluoxetine (Prozac) proved ineffective at easing the condition’s features.
The new study suggests that a drug that rapidly activates serotonin receptors would be a more effective way of treating the condition.
Malenka and his team are looking at whether drugs that activate serotonin receptors directly can enhance sociability in mouse models of autism. They are also exploring the effects of MDMA, the drug popularly known as ecstasy, which may promote serotonin release from neurons.
Read full, original post: Study revives serotonin as target for autism treatments